Yutaka Sasaki

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential

Jörgen Adolfsson, Robert Månsson, Natalija Buza-Vidas et al. · Cell · 2005 · 1.2K citations · Full text

Developmental Biology, Medicine, Hematology +7

Upregulation of Flt3 Expression within the Bone Marrow Lin−Sca1+c-kit+ Stem Cell Compartment Is Accompanied by Loss of Self-Renewal Capacity

Jörgen Adolfsson, Ole Johan Borge, David Bryder et al. · Immunity · 2001 · 691 citations · Full text

Developmental Biology, Self-renewal Capacity, Medicine +12

Impaired Allostimulatory Capacity of Peripheral Blood Dendritic Cells Recovered from Hepatitis C Virus-Infected Individuals

Tatsuya Kanto, Norio Hayashi, Tetsuo Takehara et al. · The Journal of Immunology · 1999 · 358 citations · Full text

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma

Yoshiki Ito, Yutaka Sasaki, Masayoshi Horimoto et al. · Hepatology · 1998 · 337 citations · Full text

Signal Transduction, Hepatology, Tumor Microenvironment +14